Improving Existing Therapies

Improve Existing Therapies

Adapt our novel delivery system to improve adoption of your existing therapies. 

Improve Existing Therapies

Adapt our novel delivery system to improve adoption of your existing therapies. 

Improving Effects on Joint Integrity 

Autologous stem cells have been used for decades to clinically treat joint pain but with mixed results. In fact, after numerous clinical trials, there is still no FDA approved cell therapy for osteoarthritis.

Likarda conducted animal studies demonstrating that stem cells injected directly into an osteoarthritic knee were inferior in their effect on the joint integrity and proteoglycan levels compared to the same number of cells first encapsulated in one of Likarda’s controlled release hydrogel formulations. Instead of 3 injection every 2 weeks (the typical stem cell protocol now), a single injection of cells in a hydrogel that degraded over a 6-week period resulted in healthy joints without signs of osteoarthritis.

Stand Alone Stem Cells vs Encapsulated Stem Cells

The osteoarthritic joint on the left received stem cells alone. The osteoarthritic joint on the right received the same number of stem cells encapsulated in a Likarda formulation. The joint that received the encapsulated cells had a greater effect and returned the joint to its non-arthritic condition.

Book A Call With A Scientist.

Does your cell therapy need a targeted approach? Would improving potency be a benefit for your cell therapy? Are you looking for a partner who can customize a solution that fits your exact needs? Discuss options with one of our team members today.